Clinical Trial Update: A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia [Phase 3]

View source ↗

Summary

Phase 3 long-term trial results for ETC-1002 (bempedoic acid) in adults with hypercholesterolemia were completed, with results posted in February 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• ETC-1002 (bempedoic acid)

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Hyper-low-density Lipoprotein (LDL) Cholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2026-02-20